Related Experiment Video
Updated: May 11, 2026
08:08
In Vitro Stimulation and Visualization of Extracellular Trap Release in Differentiated Human Monocyte-derived Macrophages
Published on: November 1, 2019
Spirohexenolide A targets human macrophage migration inhibitory factor (hMIF)
Wei-Lun Yu1, Brian D Jones, Minjin Kang
1Department of Chemistry and Biochemistry, University of California-San Diego, 9500 Gilman Drive, La Jolla, California 92093-0358, United States.
Journal of Natural Products
|May 11, 2013
Summary
Spirohexenolides A and B bind to and modulate human macrophage migration inhibitor factor (hMIF). This interaction is key to the compounds
Area of Science:
- Natural product chemistry
- Immunology
- Cell biology
Background:
- Spirohexenolides A and B are unique spirotetronate natural products.
- Human macrophage migration inhibitor factor (hMIF) is a key regulator of immune responses and inflammation.
Purpose of the Study:
- To identify the molecular target of spirohexenolides A and B.
- To investigate the interaction between spirohexenolides A and B and human macrophage migration inhibitor factor (hMIF).
- To elucidate the role of hMIF in the biological activity of spirohexenolides A and B.
Main Methods:
- Immunoaffinity-fluorescent labeling method was employed to study the binding interaction.
- Biochemical assays were used to characterize the properties of the interaction.
- Cell-based assays were performed to assess the cytostatic activity of the spirohexenolides.
Main Results:
- Spirohexenolides A and B were identified to bind to human macrophage migration inhibitor factor (hMIF).
- The binding interaction was characterized, detailing its properties.
- Evidence suggests that hMIF plays a crucial role in the cytostatic activity of spirohexenolides A and B.
Conclusions:
- Spirohexenolides A and B represent a novel class of hMIF modulators.
- The interaction with hMIF is critical for the observed cytostatic effects of these natural products.
- This study opens avenues for exploring spirohexenolides as potential therapeutic agents targeting hMIF-related pathways.
